TA-CIN, a vaccine incorporating a recombinant HPV fusion protein (HPV16 L2E6E7) for the potential treatment of HPV16-associated genital diseases.

摘要: Commercially available prophylactic HPV vaccines for cervical cancer prevention have limited use in women with previous viral exposure. Therefore, a therapeutic vaccine would benefit patients HPV-associated genital diseases. Being developed by Cancer Research Technology Ltd, under license from Xenova Group plc, TA-CIN (Tissue Antigen - Cervical Intraepithelial Neoplasia) is fusion protein comprising the HPV16 proteins L2, E6 and E7 treatment of HPV16-associated In mouse models, induced dose-dependent HPV16-specific CD4 CD8 T-cell responses, which were enhanced when boosted vaccinia-based vector TA-HPV (Therapeutic HPV). A phase I clinical trial healthy volunteers reported no serious adverse events cellular immune responses. Phase II trials anogenital vulval intraepithelial neoplasia investigated heterologous prime/boost strategies TA-CIN/TA-HPV TA-HPV/TA-CIN, but neither regimens offered advantages over single-agent TA-HPV. recent investigating imiquimod/TA-CIN demonstrated significant infiltration T-cells lesion responders complete regression 63% patients. More comprehensive case-controlled are needed to define immunotherapy verify its properties.